Inhibrx Biosciences Inc 2025年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedSeptember30, 2025 or Commission File Number:001-42031 INHIBRX BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) (858)795-4220 (Registrant’s telephone number, including area code) N/A Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large Accelerated Filer☐Non-accelerated filer☒ Acceleratedfiler☐Smallerreportingcompany☒Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of November7, 2025, the registrant had14,543,738shares of common stock outstanding. This Quarterly Report on Form 10-Q, or this Quarterly Report, contains express and implied forward-looking statements within themeaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities ExchangeAct of 1934, as amended, or the Exchange Act. Except as otherwise indicated by the context, references in this Quarterly Report to“we,” “us” and “our” are to the consolidated business of Inhibrx Biosciences, Inc., or the Company, or Inhibrx. All statements otherthan statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identifyforward-looking statements by words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,”“intend,” “may,” “plan,” “possible,” “potential,” “predict,” “project,” “design,” “seek,” “should,” “target,” “will,” “would,” or thenegative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statementsabout: •the design, initiation, timing, progress, results and costs of our research and development programs as well as our preclinicalstudies and clinical trials;•our ability to advance therapeutic candidates into, and successfully complete, clinical trials;•our interpretation of initial, interim or preliminary data from our clinical trials, including interpretations regarding diseasecontrol and disease response;•the potential benefits of regulatory designations;•the timing or likelihood of regulatory filings and approvals;•the safety and therapeutic benefits of our therapeutic candidates;•the commercialization of our therapeutic candidates, if approved;•the pricing, coverage and reimbursement of our therapeutic candidates, if approved;•our ability to utilize our technology platform to generate and advance additional therapeutic candidates;•the implementation of our business model and strategic plans for our business and therapeutic candidates;•our ability to successfully manufacture our therapeutic candidates for clinical trials and commercial use, if approved;•our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;•the scope of protection we are able to establish and maintain for intellectual property rights covering our therapeuticcandidates;•our ability to enter into strategic partnerships and the potential benefits of such partnerships;•future results of operations and financial position and our estimates regarding expenses, capital requirements and needs foradditional financing;•our ability to raise funds needed to satisfy our capital requirements, which may depend on financial, economic and marketconditions and other factors, over which we may have no or limited control;•our financial performance;•our and our third-party partners’ and service providers’ ability to continue operations and advance our therapeutic candidatesthrough clinical trials, as well as the ability of our third party manufacturers to provide the required r